Ultimately, a clinical trial could be planned with examination of PCa tissue pre and post lifestyle and drug intervention, including for example, in vitro co‐culture of ppWAT and PCa cells with MCP‐1/IL‐1β inhibitors, or preclinical models of ABCD with microbiome manipulation. Here, CCL2 is linked to posterior cortical atrophy.